Muhammad Sulaiman, M.Pharm (1); Prof. Dr.rer.nat. apt. Raden Rara Endang Lukitaningsih, S.Si., M.Si. (2); Dr.rer.nat. Ronny Martien, M.Si. (3); Prof. Dr. dr. Yohanes Widodo Wirohadidjojo, Sp.KK(K). (4); Prof. Dr. Med. dr. Retno Danarti, Sp.KK(K). (5)
Tanggal/Date
10 2025
Kata Kunci/Keyword
Abstrak/Abstract
Infantile hemangioma (IH) is the most prevalent benign vascular tumor among infants. While most heman-
gioma cases typically undergo spontaneous resolution, there is a risk of complications and concern over
changes in appearance in certain circumstances. The treatment options include oral and topical drug ther-
apy, laser therapy, and surgery. Because the lesions are (but not exclusively) formed on the skin’s surface
and exhibit features typical of tumors, there are opportunities for implementing nanoparticle technology for
systemic and topical treatments. Nanotechnology in drug delivery generally aims to boost the efficacy of
substance penetration or absorption, prevent systemic side effects by passive or active targeting, prolong
effectiveness, and reduce the dose and duration of treatment. Several types of nanoparticles have been se-
lected as research subjects in nanoparticle-based studies for treating IH. The type of nanoparticle is chosen
based on evaluations of many factors, such as the active substance’s physical and chemical compatibility,
target site, and route of administration, and the formula is constructed by using an optimization process,
resulting in a system with distinctive advantages.
Rumpun Ilmu
Penyakit Kulit dan Kelamin
Bahasa Asli/Original Language
English
Level
Internasional
Status
Dokumen Karya
No
Judul
Tipe Dokumen
Aksi
1
2025_RETNO DANARTI_Nanotechnology in Infantile Hemangioma Management.pdf
